|
Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.
IMG-004 is a non-covalent, reversible bruton tyrosine kinase inhibitor, and is being developed by Shanghai-based Inmagene Biopharmaceuticals for the potential treatment of immunological diseases.
Hong Kong-based biopharmaceutical company Hutchmed is currently working with Inmagene on conducting the phase one study.
The phase one study is a double-blind, randomised, placebo controlled single and multiple dose study in healthy subjects. The study will explore IMG-004's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects.
‘IMG-004 is the second novel drug candidate under the collaboration with Hutchmed which Inmagene has successfully advanced into clinical studies this year. Inmagene also expects to submit another investigational new drug application for a third novel drug candidate in 2022. Such results have demonstrated the Inmagene team's innovative and execution capabilities,’ said Inmagene Chair and CEO Jonathan Wang.
Shares in Hutchmed were up 2.0% at 234.50 pence on Tuesday morning in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
